4DMedical (ASX:4DX) Short-Term Debt: A$1.14 Mil (As of Dec. 2025)


ASX:4DX 4DMedical Ltd ASX:4DX
64 GF Score
Price A$4.06
GF Value A$1.45
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is 4DMedical Short-Term Debt?

4DMedical ASX:4DX -0.98% 64 Short-Term Debt is A$1.14 Mil as of Dec. 2025. GuruFocus rates ASX:4DX with a GF Score™ of 64/100 and a GF Value™ of A$1.45 (Significantly Overvalued). The stock has 2 warning signs investors should review.

4DMedical's Short-Term Debt for the quarter that ended in Dec. 2025 was A$1.14 Mil.

4DMedical's quarterly Short-Term Debt declined from Dec. 2024 (A$1.04 Mil) to Jun. 2025 (A$0.00 Mil) but then increased from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$1.14 Mil).

4DMedical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

4DMedical Short-Term Debt Related Terms

4DMedical Short-Term Debt Historical Data

* Premium members only.

The historical data trend for 4DMedical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4DMedical Short-Term Debt Chart

4DMedical Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

4DMedical Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.00 1.04 0.00 1.14
ASX:4DX
64GF Score
4DMedical Ltd ASX:4DX
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of A$1.14 Mil mean?
4DMedical (ASX:4DX) has a Short-Term Debt of A$1.14 Mil as of Dec. 2025.
Is 4DMedical's Short-Term Debt too high?
4DMedical's current Short-Term Debt is A$1.14 Mil. Overall, 4DMedical has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 4DMedical's Short-Term Debt compare to ABT and SYK?
4DMedical's Short-Term Debt of A$1.14 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. 4DMedical's current Short-Term Debt is A$1.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4DMedical stock overvalued right now?
Based on GuruFocus' analysis, 4DMedical (ASX:4DX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$1.45, compared to a current price of A$4.06 — trading 180% above its estimated fair value. The current Short-Term Debt is A$1.14 Mil. 4DMedical's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For 4DMedical (ASX:4DX), the current Short-Term Debt is A$1.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 4DMedical (ASX:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, 4DMedical stock appears to be overvalued. The current stock price of A$4.06 is trading 180% above its estimated GF Value™ of A$1.45. GuruFocus considers 4DMedical to be Significantly Overvalued.

Key valuation signals for ASX:4DX:

  • Short-Term Debt: A$1.14 Mil
  • GF Value™: A$1.45 vs. price of A$4.06 (180% above fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ASX:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4DMedical Business Description

Other Exchanges FDMDF:USAMQ7:Germany
Address 700 Swanston Street, Level 7, Melbourne Connect, Carlton, VIC, AUS, 3053
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
64GF Score

Get the complete analysis for ASX:4DX

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$4.06
Price
A$1.45
GF Value